** Shares of Tylenol maker Kenvue KVUE.N rise 4.2% to $24.08 premarket
** KVUE says it earned a profit of 24 cents per share vs analysts' estimates of 23 cents per share - data compiled by LSEG
** Reports Q1 revenue of $3.74 billion vs estimates of $3.67 billion
** KVUE expects 2025 profit to remain flat year-over-year, anticipating higher costs from President Trump's tariffs on U.S. imports
** Co had previously forecast 2025 profit to be flat to 2% growth
** Separately, company appoints Amit Banati as chief financial officer, effective May 12
** Up to last close, stock has risen 8.2% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。